Seqster Partners with Takeda to Help Digitally Transform Patient Experiences

Rhea-AI Summary

Seqster PDM Inc. and Takeda Pharmaceutical Company Limited have extended their partnership to enhance patient outcomes by leveraging Seqster's healthcare technology. The collaboration will provide Takeda with immediate access to Seqster's secure platform, which integrates electronic health records, genomic data, and wearable information. This will facilitate real-time data visualization, improving patient engagement and compliance during clinical trials. The implementation will enable Takeda to activate 12 use cases across its business rapidly, aiming to enhance clinical development and patient services.

Positive

• Enhanced patient outcomes through improved access to real-world data.
• Acceleration of clinical development and patient engagement via Seqster's technology.
• Rapid integration and implementation of 12 distinct use cases within weeks.

Negative

• None.

SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Seqster PDM Inc. ("Seqster") the award winning healthcare technology company and Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") announced today an extended agreement to improve patient outcomes through better access and understanding of patient-level data.

Seqster will provide Takeda with instant access to its secure platform to visualize longitudinal electronic health records (EHRs), genomic profiles (DNA), and wearable/fitness data across health systems for individual patients. Seqster's technology supports real-time, real-world data and targeted patient engagement, which includes FDA 21 CFR Part 11 compliance.

"By leveraging Seqster and extending Takeda's external data and digital collaboration ecosystem, we will have better access to real-world evidence, integrating real-time into our workflows generating powerful data and insights for research and patient services," explained Dr. Emir Roach, Head of Emerging Technologies & Digital Partnerships, Global IT at Takeda. "Speed to implementation and integration with Takeda's infrastructure will allow us to activate 12 distinct use cases across our business in a matter of weeks- ultimately, positively impacting patient outcomes."

Seqster's decision support system and research platform dramatically reduces the time for consenting and onboarding patient data during clinical trials. This enhances patient engagement and compliance through a single-entry point for EHRs and integrates with partners enterprise data backbones.   

"We appreciate having a patient-focused partner like Takeda. Takeda's strategic approach to adding Seqster's technology capabilities into its data and digital foundation maximizes the full potential and rapid deployment of our platform," stated Ardy Arianpour, Seqster's CEO and Co-Founder.

Arianpour further explained, "The broad implementation of Seqster across therapeutic areas and business units positions both companies at the forefront of the global digital health transformation. Our technology will help Takeda accelerate transforming clinical development in the post-COVID era, improving patient engagement and services, and streamlining safety and efficacy demonstration. By serving as one of Takeda's collaborators in their digital ecosystem, Seqster is positioned as a leading patient-centric technology to help patients in their healthcare journey."

ABOUT SEQSTER
Seqster is a SaaS-based healthcare technology company that enables organizations to drive efficient healthcare via comprehensive medical records (EHR), individual genomic profiles (DNA), and personal health device data. For the first time, users create their own matched, longitudinal health data profile across all of their US-based healthcare data sources through person-centric interoperability. The company serves healthcare enterprises such as pharmaceutical companies, payers, life insurance, and providers.

The platform is both FDA 21 CFR PART 11 & CMS-ONC 21st Century Cures Act Compliant. Seqster is hosted on HIPAA-compliant and HITRUST certified servers. It connects users to more than 3,000 hospitals and health systems and over 150,000 doctor offices and medical clinics nationwide. Seqster is privately held and headquartered in San Diego.

If you are interested in partnering with Seqster, please contact: bd@seqster.com

Learn more about our technology at seqster.com, follow us @Seqster

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/seqster-partners-with-takeda-to-help-digitally-transform-patient-experiences-301162445.html

SOURCE Seqster

FAQ

What is the new partnership between Seqster and Takeda about?

Seqster and Takeda have extended their partnership to improve patient outcomes by integrating Seqster's healthcare technology, allowing access to comprehensive patient data.

How will Seqster's platform affect Takeda's clinical trials?

Seqster's platform will streamline patient data onboarding and enhance engagement, thereby improving compliance and efficiency during clinical trials for Takeda.

What compliance measures does Seqster's technology have?

Seqster's platform is compliant with FDA 21 CFR Part 11 and the CMS-ONC 21st Century Cures Act, ensuring secure handling of patient data.

How quickly can Takeda implement Seqster's technology?

Takeda is expected to activate 12 distinct use cases within weeks, showcasing rapid implementation capabilities.

What are the benefits of the Seqster and Takeda partnership?

The partnership will enhance patient engagement and outcomes, improve clinical development efficiency, and provide real-time access to patient-level data.